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Abstract: Bioluminescent imaging (BLI) is particularly well suited for imaging small animals, and it can be readily used by scientists
who are already routinely using the luciferase gene as a reporter in cell-based assays. This strategy relies on ATP and an O2
dependent photochemical reaction between luciferin and luciferase, resulting in the release of photons from only live cells. In BLI,
the intensity of the light detected by the device is proportional to the intensity of light emitted and the relationship is quantitative.
This study was performed to determine the sensitivity of BLI for the imaging of lung metastasis and breast cancer models in addition
to primary flank tumors. A549 lung cancer and MDA-MB 231 breast cancer cell lines were transfected with a lentiviral construct
containing the luciferase gene and transfected cells were used as xenograft animal models. BLI was used to monitor tumor
development and growth. Noninvasive bioluminescent imaging in vivo provides easy visualization of the tumor size and location so
that imaging results can be used as an indicator of the treatment effectiveness, potentially accelerating the optimization of cancer
treatment protocols.
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Introduction
Molecular events promoting tumorigenesis and
anticancer therapeutic strategies have been intensively
studied in tumor cell culture models. In the past few
years, bioluminescence imaging (BLI) has emerged as a
powerful strategy for the validation of cell culture
findings in animal models of cancer. Knowledge of the
kinetics of the bioluminescent signals is required for the
reliable quantification and comparison of signals during
longitudinal studies (1-3). The objective of this study was

to analyze the time course of luminescent signals emitted
from luciferase-expressing cells in flank tumors, lung
metastasis and breast cancer models.
BLI is made possible through the use of chargecoupled (CCD) cameras along with the photon emitting
properties of a particular enzyme-substrate reaction.
Bioluminescence, the conversion of chemical energy into
light in living organisms, is dependent on 2 principal
components, an enzyme luciferase and the substrate
D-luciferin (4,5).

Luciferase
ATP + D-luciferin + O2

Oxyluciferin + AMP + Ppi + CO2 + light

* This study was carried out in The University of Texas Southwestern Medical Center, Departments of Cell Biology, Radiology and Cancer Imaging
Program.
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The enzyme and substrate coupling causes photonreleasing chemical reactions, and the light produced has
emission spectra ranging from 400 nm to 620 nm, which
are detected by a CCD camera (Scientific Imaging
Technologies Inc., Tigard, OR, USA (SITe) SI-032AB
CCD). Cooling of the CCD camera can significantly reduce
background dark current signals. The low background of
luminescence from normal tissue and the rapid turnover
of the luciferase enzyme make this method ideally suited
for temporal in vivo imaging of gene expression.
Following treatment of tumor bearing mice with various
anti-cancer drugs, the emitted light can be recorded
quantitatively and the increase or decrease in tumor size
can be easily monitored (6-12).
Single head optical imaging system (Cyclops):
Cyclops is an optical imaging system based on a backilluminated, high quantum efficiency CCD camera that has
particularly high sensitivity (quantum efficiency 80%85%) with a flat response from blue to near infrared and
longer wavelengths. Light exposure is controlled using a
mechanical shutter, which allows for very short exposure
times (< 5 ms) and eliminates the smear effect observed
in full frame CCD cameras without a shutter. This
architecture provides a high dynamic range combined
with very low readout noise. As the CCD camera is very
sensitive to light, it is encapsulated in a light-tight
enclosure and can be automatically positioned at the
desired distance from the subject in order to adjust the
field of view. The duration of the imaging varies on the
intensity of the bioluminescent signal.
Multi head optical imaging system (light emission
tomograpy system): Multiple high sensitivity CCD
cameras simultaneously record views and a computer
controlled rotation mechanism allows imaging at multiple
angular positions, as required for three dimensional
reconstructions. An optical imaging system with 5
cameras that surround the subject in the transverse plane
was designed for permitting the simultaneous acquisition
of images from 5 points of view 72° apart. A
computerized system can rotate the cameras around the
longitudinal axis to provide a more complete angular
coverage (Figure 1).
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Materials and Methods
Generation of luciferase expressing cell lines: The
A549 lung adenocarcinoma cell line and MDA-MB 231
breast carcinoma cells were obtained from ATCC. MDAMB 231 breast carcinoma cells were grown in a 4:1
mixture of Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% cosmic calf serum (HyClone),
whereas A549 lung carcinoma cells were grown in F12
media (Gibco) supplemented with 10% FBS (Invitrogen).
The A549-Luc and MDA-MB 231-Luc cell lines were
established using a lentivirus encoding the luciferase gene
driven by a Ubiquitin promoter. These lentiviral
expression plasmids encode for the HIV-1-Gag-pol, HIV1-Reverse transcriptase and HIV-1-VSV-G envelope
proteins. The 293T cells, a packaging cell line for
lentivirus, were grown in DMEM (10% FCS, Invitrogen)
at 37 ºC, 5% CO2. The lentiviral vectors (CW-GagPol,
CMW-Rev and CMV-VSV-G) were co-transfected into
293T cells using Fugene 6 (Roche Biosciences) overnight
(14-16 h) at 37 ºC. Virus containing medium was
collected and filtered (0.45 µm) after 24, 36 and 48 h.
and replaced with fresh DMEM (10% FCS, Invitrogen)
each time. The A549 and MDA-MB 231 cells were
infected with the virus containing medium supplemented
with 10 mg/ml of DEAE-Dextran. After infection, the
virus containing medium was replaced with fresh medium
to allow the cells to recover for 24 h. The cells were then
plated at 3 x 104 per 10 cm dish and placed under
selection of G418 at 500 µg/ml for 2 weeks.
Xenograft animal models: Immunodeficient mice
(Nu/Nu; Harlan Sprague Dawley, Inc., Indianopolis, IN,
USA) were maintained in pathogen-free conditions within
the animal resources center (ARC) at the University of
Texas Southwestern Medical Center. The mice were
irradiated with 350 rad 137Cs, 18-24 h before the
injection of tumor cells.
A549-Luc cells were assessed for tumorigenicity in
both an intravenous metastasis model and a subcutaneous
flank tumor model, whereas MDA-MB 231-Luc cells were
used for the breast cancer model. A549-Luc cells and
MDA-MB 231-Luc cells were grown until about 70%
confluence just 1 day before injection. After checking cell
viability with trypan blue, A549-Luc cells were diluted in
PBS at a final concentration of 1 x 106 cells/100 µl PBS
for tail vein injection. For mammary fat pad injections,
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Results
The kinetics of luciferase expression were analyzed
after intraperitoneal luciferin (6 mg/kg) injection and the
highest signal was obtained after 8-10 min. The signal
decreased within 60 min (Figure 2). As the technique
does not harm the animals, multiple sequential imaging
studies in the same animal are possible. At the
concentrations used for bioluminescence imaging,
D-luciferin is nontoxic and nonimmunogenic, and so serial
imaging examinations can be performed with the same
mouse. D-luciferin crosses cell membranes and penetrates
the intact blood-brain barrier in addition to placental
barriers after injection in mice, allowing this reporter
protein to be imaged in any anatomic site.

6

2 x 10 MDA-MB 231-Luc cells/200 µl PBS were injected
on both sides subcutaneously. For flank tumors, 4 x 106
6
cells/400 µl PBS for the right flank and 2 x 10 cells/200
µl PBS for the left flank tumor model were used and
imaged by BLI.
Bioluminescent imaging: The light-sensitive
substrate, D-luciferin (Biosynth), was kept at 4 ºC in
darkness and given by intravenous, intraperitoneal or
subcutaneous (150 mg/kg) injection. The mice were
placed under the CCD camera and kept under isoflurane
anesthesia (1.5%-2.0%) during imaging. The images
were taken 8-10 min after the D-luciferin injection.
Generally the test animal was exposed to the CCD for 8
min (Figure 2). With the use of computer image analyses
software (Igor Pro), color images of the tumor overlaid
upon a picture of the particular mouse were created.
Relative intensities of emitted light were represented as a
pseudocolor image ranging from blue (least intense) to
red (most intense).
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Figure 1. LETS (Light Emission Tomography System).

A549-Luc cells were assessed for tumorigenicity in
both an intravenous metastasis model and a subcutaneous
flank tumor model. After the injection of A549-Luc cells
by tail vein, weekly serial in vivo images were taken from
the animals. The lung metastases developed 3 weeks
after the tail vein injection and continued to grow (Figure
3). Levels of bioluminescence from in vivo images
corresponded to the frequency and size of metastatic
lesions in lungs as well as flank and breast tumors as
subsequently confirmed by histology (data not shown).
After the subcutaneous injection of A549-Luc cells,
usually 1-2 days is enough to get signal from flank
tumors in nude mice. The image 1 week after flank
injections is given in Figure 4; 4 x 106 A549-Luc cells
were injected into the left flank area and 2 x 106 cells into
the right flank.
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Figure 2. Kinetics of luciferase expression in A549-Luc cells after 6
mg/kg D-luciferin injection.
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6

Figure 3. Lung metastases formed 3 weeks after tail vein injection of A549-Luc cells (1x10 ). The image on the left side is 3 weeks after injection,
the right one is 4 weeks after injection.

MDA-MB 231-Luc cells were used for the mammary
fat pad model. Following a 0.5-1 cm incision, 2 x 106
MDA-MB 231-Luc cells were implanted on both fat pad
areas. Visible tumors developed within 1-2 weeks on both
sides (Figure 5).
The quantitative results of BLI are summarized in the
Table.

Discussion
In our study, we constituted xenograft animal models
by using A549-Luc and MDA-MB 231-Luc cells and a
bioluminescence imaging system for monitoring the
tumors formed by luciferase expressing cancer cells. By
using a single CCD, it was recognized that a problem
appears in the quantification of the light emitted from a
tumor or organ inside an animal because internal organs,
muscles, and bones can partially or totally obscure the
area of interest in the direction of imaging. To overcome
this problem, the animals were imaged by light emission
tomograpy system (LETS), a novel optical imaging system

Figure 4. Flank tumors developed 1 week after subcutaneous injection
of A 549-Luc cells (4x106 /left flank, 2x106/ right flank).

Table. Quantitative results of bioluminescent imaging.
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Lung metastasis model

7
1.421x10 (3 weeks)

8.619x107 (4 weeks)

Flank model

1.985x108 (left side)

3.346x106 (right side)

Breast cancer model

6.695x10 (left side)

7

4.986x10 (right side)

7
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Figure 5. Breast tumours formed by MDA-MB 231-Luc cells (2x106/each fat pad). The image on the left side is left fat pad and on the right side is
right fat pad.

that combines the features of a radiologic tomography
unit and multiple CCD cameras, being designed to
measure quantitatively the light escaping the body over a
complete set of angles (9,10).
This is the first study in which 3 dimensional LETS has
been used for xenograft animal experiments. It is clear
that additional cameras provide increased sensitivity and
provide better time resolution. We have shown the
efficiency of LETS, especially in detecting
micrometastases within 3 weeks of tail vein injection,
breast tumors within 1-2 weeks of implantation and flank
tumors 1-2 days after subcutaneous injection.
These xenograft animal models in combination with a
non-invasive in vivo imaging system may be useful for
devising new therapies. The therapeutic effects of the
drug can be assessed without having to sacrifice the mice
since Luc-expressing cells can be monitored frequently,
quantitatively and non-invasively with ease in real time.
Statistically significant results can be achieved by using a
small number of mice since multiple longitudinal
measurements can be obtained over time (9,10). The
conventional methods used to date to test the effect of
novel therapies are time and labor-consuming. In
addition, BLI instruments are considerably cheaper than
those necessary for other modalities such as CT, MRI,
PET and SPECT and the technology does not require the
use of radionuclides, with their associated hazards
(11,12).

In principle, fluorescent imaging of GFP should be
more sensitive than BLI. However, fluoresence imaging is
confounded by intense autofluoresence and in practice the
2 techniques show similar sensitivity. In some cases, BLI
has been shown to be more sensitive than fluorescent
GFP imaging. Luciferase-expressing tumors were
detected as early as 1 day after tumor cell inoculation,
whereas GFP-expressing tumors were not detected until
7 days later. Compared to bioluminescent imaging,
fluorescent imaging does not require the injection of a
substrate and may be appropriate for applications where
sensitivity is not critical (13). In addition, another imaging
group suggested that GFP-transfected cells may be useful
for imaging studies of superficial tumors where both
excitation and emission wavelengths are able to penetrate
tissues, whereas luciferase-transfected cells appear
superior for imaging studies of primary and metastatic
tumors in distant sites and deep tissues (14).
Animal experiments are an important step providing
insight for planning phase I clinical trials. In vivo imaging
of luciferase - expressing tumor cells is a useful tool to
investigate the dynamics of tumor growth and metastasis
as well as the efficacy of anticancer treatment in animal
models (10). Its application to traditional oncology animal
models offers quantitative and sensitive analysis of tumor
growth and metastasis (15). BLI can also be used to
either track the course of an infection (viral, bacterial) or
monitor the efficacy of antimicrobial therapies. By
combining molecular biology with molecular in vivo
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imaging modalities, it is possible to get functional
information about disease processes in living systems
(16). The future use of this technology may help in
survival studies of the luciferase - expressing cells after
implantation (stem cells, myoblasts, hematopoetic cells),
the response of the host to the infections and disease
processes that cannot be detected by conventional
imaging.
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